JP2022505663A - IgM-Fcベース及びIgA-Fcベースの多価結合分子 - Google Patents

IgM-Fcベース及びIgA-Fcベースの多価結合分子 Download PDF

Info

Publication number
JP2022505663A
JP2022505663A JP2021522078A JP2021522078A JP2022505663A JP 2022505663 A JP2022505663 A JP 2022505663A JP 2021522078 A JP2021522078 A JP 2021522078A JP 2021522078 A JP2021522078 A JP 2021522078A JP 2022505663 A JP2022505663 A JP 2022505663A
Authority
JP
Japan
Prior art keywords
binding
fragment
binding molecule
multimer
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021522078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505663A5 (cg-RX-API-DMAC7.html
Inventor
ラメシュ バリガ
ポール ヒントン
ディーン エン
ブルース アラン キート
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2022505663A publication Critical patent/JP2022505663A/ja
Publication of JP2022505663A5 publication Critical patent/JP2022505663A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021522078A 2018-10-23 2019-10-23 IgM-Fcベース及びIgA-Fcベースの多価結合分子 Pending JP2022505663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749429P 2018-10-23 2018-10-23
US62/749,429 2018-10-23
PCT/US2019/057702 WO2020086745A1 (en) 2018-10-23 2019-10-23 MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES

Publications (2)

Publication Number Publication Date
JP2022505663A true JP2022505663A (ja) 2022-01-14
JP2022505663A5 JP2022505663A5 (cg-RX-API-DMAC7.html) 2022-10-28

Family

ID=70331240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522078A Pending JP2022505663A (ja) 2018-10-23 2019-10-23 IgM-Fcベース及びIgA-Fcベースの多価結合分子

Country Status (11)

Country Link
US (1) US20210380701A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870223A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022505663A (cg-RX-API-DMAC7.html)
KR (1) KR20210083260A (cg-RX-API-DMAC7.html)
CN (1) CN112839677A (cg-RX-API-DMAC7.html)
AU (1) AU2019368289A1 (cg-RX-API-DMAC7.html)
CA (1) CA3113268A1 (cg-RX-API-DMAC7.html)
IL (1) IL281901A (cg-RX-API-DMAC7.html)
MX (1) MX2021004660A (cg-RX-API-DMAC7.html)
SG (1) SG11202103720XA (cg-RX-API-DMAC7.html)
WO (1) WO2020086745A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CA3055790A1 (en) 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
JP2023522962A (ja) * 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド Pd-1アゴニスト多量体結合分子
CN116813759B (zh) * 2022-03-21 2025-11-28 中国科学院微生物研究所 纳米抗体r14的构建体及其应用
CA3245061A1 (en) * 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T-CELL RECEIVER MULTIMERS AND THEIR USES
CN118369336A (zh) * 2022-04-15 2024-07-19 Im生技股份有限公司 具有改进半衰期的融合蛋白平台
US20240025996A1 (en) * 2022-07-11 2024-01-25 Fred Hutchinson Cancer Center Igm-multimerized single-domain antibodies that bind ror1
CN117466996A (zh) * 2022-07-29 2024-01-30 深圳市新产业生物医学工程股份有限公司 新型冠状病毒检测试剂盒及应用
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
CN119505007A (zh) * 2023-08-23 2025-02-25 菲鹏生物股份有限公司 免疫球蛋白Fc区或恒定区

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515731A (ja) * 1996-06-14 2000-11-28 スミスクライン・ビーチャム・コーポレイション 6量体融合タンパク質およびその使用
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス, インコーポレイテッド IgA多重特異性結合分子
WO2018017888A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
WO2018017889A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
JP2018503401A (ja) * 2015-01-20 2018-02-08 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP2018508214A (ja) * 2015-03-04 2018-03-29 アイジーエム バイオサイエンシズ インコーポレイテッド Cd20結合分子およびその使用方法
JP2018513680A (ja) * 2015-03-25 2018-05-31 アイジーエム バイオサイエンシズ エー/エス 多価b型肝炎ウイルス抗原結合分子およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604693T3 (pl) * 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
CA3055790A1 (en) * 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515731A (ja) * 1996-06-14 2000-11-28 スミスクライン・ビーチャム・コーポレイション 6量体融合タンパク質およびその使用
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス, インコーポレイテッド IgA多重特異性結合分子
JP2018503401A (ja) * 2015-01-20 2018-02-08 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP2018508214A (ja) * 2015-03-04 2018-03-29 アイジーエム バイオサイエンシズ インコーポレイテッド Cd20結合分子およびその使用方法
JP2018513680A (ja) * 2015-03-25 2018-05-31 アイジーエム バイオサイエンシズ エー/エス 多価b型肝炎ウイルス抗原結合分子およびその使用
WO2018017888A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
WO2018017889A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUR. J. IMMUNOL., vol. 42, JPN6023035490, 2012, pages 1354 - 1356, ISSN: 0005308184 *

Also Published As

Publication number Publication date
WO2020086745A1 (en) 2020-04-30
AU2019368289A1 (en) 2021-04-29
KR20210083260A (ko) 2021-07-06
MX2021004660A (es) 2021-05-28
CA3113268A1 (en) 2020-04-30
IL281901A (en) 2021-05-31
EP3870223A4 (en) 2022-08-24
US20210380701A1 (en) 2021-12-09
SG11202103720XA (en) 2021-05-28
EP3870223A1 (en) 2021-09-01
CN112839677A (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
US20210380701A1 (en) MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
JP6929827B2 (ja) Asgpr抗体およびその使用
TWI837156B (zh) 新穎的cd137及pd-l1特異性融合蛋白
US20190016771A1 (en) Trimeric costimulatory tnf family ligand-containing antigen binding molecules
US20250101123A1 (en) Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
EP4013792A1 (en) Immunostimulatory multimeric binding molecules
KR20200079492A (ko) 이중특이성 2+1 컨터체
JP2019524053A (ja) Tnfファミリーリガンドトリマーとpd1結合部分とを含む抗原結合分子
WO2020163646A1 (en) Anti-gitr antigen-binding domains and uses thereof
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
WO2023045977A1 (zh) 白介素2突变体以及其融合蛋白
US20200277392A1 (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
JP2023509952A (ja) 新規4-1bbl三量体含有抗原結合分子
CN119143873A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
JP2020536552A5 (cg-RX-API-DMAC7.html)
JP2020536552A (ja) Ctla−4変異型免疫調節タンパク質およびそれらの使用
KR20220050166A (ko) Igm 글리코변이체
KR20230113752A (ko) Cd39 및 tgf베타를 표적화하는 신규 접합체 분자
EP4408877A2 (en) Immunocytokine containing il-21r mutein
CN118355024A (zh) 包含il-21r突变蛋白的免疫细胞因子
TW202334203A (zh) 新穎的ox40及pd-l1特異性融合蛋白
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240422